Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNT with FLOT, pembrolizumab, and short-course radiotherapy for resectable esophagogastric junction adenocarcinoma
jRCT2031250089Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab, docetaxel, oxaliplatin, folinic acid and fluorouracil in gastroesophageal junction adenocarcinoma, sponsored by Merck & Co. Primary endpoint: 3-year event-free survival rate. Started Aug 2025; status: recruiting.
02
Drugs
03
Conditions
gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2031250089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250089.